Literature DB >> 18488083

Chagas disease cardiomyopathy: current concepts of an old disease.

Angelina M B Bilate1, Edecio Cunha-Neto.   

Abstract

Chagas disease continues to be a significant public health problem, as ca. 10 million people are still infected with T. cruzi in Latin America. Decades after primary infection, 30% of individuals can develop a form of chronic inflammatory cardiomyopathy known as Chagas disease cardiomyopathy (CCC). Data from both murine models and human studies support the view that an autoimmune response as well as a parasite-driven immune response involving inflammatory cytokines and chemokines may both play a role in generating the heart lesions leading to CCC. This review aims to summarize recent advances in the understanding of the immunopathogenesis of Chagas disease cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18488083     DOI: 10.1590/s0036-46652008000200001

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  36 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 2.  A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature.

Authors:  Maria Ângela B Trindade; Noemia B Carvalho; Elaini C Belfort; Carla Pagliari; Erika Gakiya; Neusa Y Sakai-Valente; Gil Benard; Maria A Shikanai-Yasuda
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 3.  Pathogenesis of chagas' disease: parasite persistence and autoimmunity.

Authors:  Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

4.  Expression of cytokines and chemokines and microvasculature alterations of the tongue from patients with chronic Chagas' disease.

Authors:  Sanivia A de Lima Pereira; Viviane O Severino; Narayane L M Kohl; Denise B R Rodrigues; Polyanna M Alves; Juliana T Clemente-Napimoga; Marlene A dos Reis; Vicente P A Teixeira; Marcelo H Napimoga
Journal:  Parasitol Res       Date:  2009-06-10       Impact factor: 2.289

Review 5.  Interferon-γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy.

Authors:  Ludmila Rodrigues Pinto Ferreira; Amanda Farage Frade; Monique Andrade Baron; Isabela Cunha Navarro; Jorge Kalil; Christophe Chevillard; Edecio Cunha-Neto
Journal:  World J Cardiol       Date:  2014-08-26

6.  Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Constança Carvalho Britto; Ana Carolina Mondaine Rodrigues; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  PLoS One       Date:  2011-07-26       Impact factor: 3.240

7.  Selective decrease of components of the creatine kinase system and ATP synthase complex in chronic Chagas disease cardiomyopathy.

Authors:  Priscila Camillo Teixeira; Ronaldo Honorato Barros Santos; Alfredo Inácio Fiorelli; Angelina Morand Bianchi Bilate; Luiz Alberto Benvenuti; Noedir Antonio Stolf; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

8.  Tambjamines and Prodiginines: Biocidal Activity against Trypanosoma cruzi.

Authors:  Rocío Herráez; Roberto Quesada; Norma Dahdah; Miguel Viñas; Teresa Vinuesa
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

9.  Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10.

Authors:  Luciana Gabriel Nogueira; Ronaldo Honorato Barros Santos; Barbara Maria Ianni; Alfredo Inácio Fiorelli; Eliane Conti Mairena; Luiz Alberto Benvenuti; Amanda Frade; Eduardo Donadi; Fabrício Dias; Bruno Saba; Hui-Tzu Lin Wang; Abilio Fragata; Marcelo Sampaio; Mario Hiroyuki Hirata; Paula Buck; Charles Mady; Edimar Alcides Bocchi; Noedir Antonio Stolf; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25

10.  Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease.

Authors:  Romina A Cutrullis; Patricia B Petray; Edgardo Schapachnik; Rubén Sánchez; Miriam Postan; Mariela N González; Valentina Martín; Ricardo S Corral
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.